ArticleTranslational vision science & technology2026
Impact of Optical Coherence Tomography Angiography Scan Protocols on Quantitative Microvascular Biomarkers in Diabetic Retinopathy.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate the influence of optical coherence tomography angiography (OCTA) scan protocols on quantitative measurements of diabetic retinopathy (DR) biomarkers and their diagnostic performance for DR staging. Methods: In this cross-sectional study, 110 eyes from 74 treatment-naïve patients with DR underwent OCTA imaging using 6 × 6 mm, 12 × 12 mm, and 29 × 24 mm scan protocols. OCTA biomarkers, including nonperfusion index (NPI), intraretinal microvascular abnormalities (IRMAs) counts, and neovascularization (NV) counts, were analyzed. Receiver operating characteristic (ROC) analysis evaluated performance for discriminating proliferative DR (PDR) from nonproliferative DR (NPDR), and advanced-stage DR (severe NPDR and PDR) from early-stage DR (mild-moderate NPDR). Results: NPI and IRMA counts increased with wider scan protocols across DR severities, with higher NV detection in PDR on wider scans. NPI showed higher performance with 29 × 24 mm scans in discriminating PDR from NPDR (0.86; 95% confidence interval [CI] = 0.79-0.93) and advanced from early DR (0.92; 95% CI = 0.88-0.97) compared with smaller scan protocols. In 6 × 6 mm scans, the combined NPI and IRMA counts outperformed NPI for discriminating advanced from early DR (0.87; 95% CI = 0.81-0.94 vs. 0.81; 95% CI = 0.72-0.89) and PDR from NPDR (0.82; 95% CI = 0.74-0.91 vs. 0.73; 95% CI = 0.62-0.83). Conclusions: Wider scan protocols captured greater burden of nonperfusion and microvascular abnormalities. NPI serves as a robust standalone biomarker across protocols. When imaging is limited to smaller fields, combining NPI and IRMA counts improves staging performance. Translational Relevance: OCTA scan protocol selection influences quantitative assessment of DR biomarkers and may guide imaging strategies for clinical staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.